Background. There is no definitive conclusion so far on the predictive values of ERCC1 polymorphisms for clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.